NRAS and neoplasm: Furthermore MAPK signalling is activated in over 90% of human melanomas [71] and our immunohistochemical analysis showed that despite an absence of exonic mutations in braf or nras, both tail tumours but not the eye tumour had activated MAPK signalling.